Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 236

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction: A Substudy of the Scandinavian Simvastatin Survival Study

Open access
Gerdes, Lars Ulrik, Gerdes, Christian, Kervinen, Kari, Savolainen, Markku, Klausen, Ib Christian, Hansen, Peter Steen, Kesäniemi, Y. Antero, Færgeman, Ole · 2000 · Circulation

Abstract

Background —Carriers of the ε4 allele of the apolipoprotein E gene are at a higher risk of coronary heart disease than individuals with other genotypes. We examined whether the risk of death or a major coronary event in survivors of myocardial infarction depended on apolipoprotein E genotype and whether the benefits of treatment with simvastatin differed between genotypes. Methods and Results —Cox proportional hazards models were used to analyze 5.5 years of follow-up data from 966 Danish and Finnish myocardial infarction survivors enrolled in the Scandinavian Simvastatin Survival Study. A total of 16% of the 166 ε4 carriers in the placebo group died compared with 9% of the 312 patients without the allele, which corresponds to a mortality risk ratio of 1.8 (95% confidence interval, 1.1 to 3.1). The risk ratio was unaffected by considerations of sex, age, concurrent angina, diabetes, smoking, and serum lipids in multivariate analyses. Simvastatin treatment reduced the mortality risk to 0.33 (95% confidence interval, 0.16 to 0.69) in ε4 carriers and to 0.66 (95% confidence interval, 0.35 to 1.24) in other patients ( P =0.23 for treatment by genotype interaction). Apolipoprotein E genotype did not predict the risk of a major coronary event. Baseline serum levels of lipoprotein(a) also predicted mortality risk and could be combined with ε4-carrier status to define 3 groups of patients with different prognoses and benefits from treatment. Conclusions —Myocardial infarction survivors with the ε4 allele have a nearly 2-fold increased risk of dying compared with other patients, and the excess mortality can be abolished by treatment with simvastatin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.101.12.1366

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 236

Metadata

Authors
Gerdes, L. U., Gerdes, C., Kervinen, K., Savolainen, M., Klausen, I. C., Hansen, P. S., Kesäniemi, Y. A., & Færgeman, O.
Venue
Circulation
Published
2000-03-28
Volume
101
Issue
12
Pages
1366-1371
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1996359690
Cited by
236
References
4
FWCI
20.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction: A Substudy of the Scandinavian Simvastatin Survival Study. https://app.cochat.ai/papers/10.1161/01.cir.101.12.1366
The paper
Gerdes, L. U., Gerdes, C., Kervinen, K., Savolainen, M., Klausen, I. C., Hansen, P. S., Kesäniemi, Y. A., & Færgeman, O. (2000). The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction: A Substudy of the Scandinavian Simvastatin Survival Study. Circulation. https://doi.org/10.1161/01.cir.101.12.1366

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.